Mumbai: Ranbaxy Laboratories has launched the generic version of Omeprazole capsules, used in the treatment of acid related diseases in the US healthcare system.
“Ranbaxy Pharmaceuticals Inc (RPI), the wholly-owned subsidiary of Ranbaxy Laboratories under an agreement with AstraZeneca Pharmaceuticals has launched an authorised generic of Omeprazole 40 mg capsules in the US,” the company said in a filing to the Bombay Stock Exchange.
“We welcome the opportunity to market an authorised generic of Omeprazole 40 mg capsules that will be commercialised immediately to all classes of trade in the US healthcare system under Ranbaxy lebel,” RPI Vice-President, Sales and Distribution, Jim Meehan said.
“We will offer this product as an affordable and accessible generic formulations to patients requiring this medication,” Meehan added.
RPI is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.
Shares of the company were trading at Rs494.40, up 2.73% on the Bombay Stock Exchange in morning trade.